Newsroom | Precision AQ

Michael Winston Appointed Chief Financial Officer of Precision AQ to Support Continued Growth

Written by Precision Communications | Nov 18, 2026, 2:12:55 PM

BETHESDA, Md. (November 18, 2026) Precision AQ, a global commercialization partner built to guide life sciences innovators through commercial complexity, today announced the appointment of Mike Winston as Chief Financial Officer (CFO). Mike brings more than 15 years of financial and operational senior leadership experience, with a proven track record of helping organizations accelerate growth, scale effectively, and navigate periods of significant transformation.

Mike joined Precision Medicine Group (Precision) in January 2022, serving in progressively broader financial and operational leadership roles within Precision for Medicine, the biomarker-driven clinical research and development business of Precision. He joined as Chief Financial Officer of Translational Sciences and most recently served as its Chief Operating Officer, with responsibility spanning financial performance, operations and client delivery. The breadth of Mike’s experience within Precision, combined with his background in finance, corporate development and business transformation, gives him a distinctive perspective on the opportunities ahead for Precision AQ.

"As Precision AQ enters its next phase of growth, having a leader who already knows the Precision business and has experience scaling technology and service businesses is a significant advantage," said Jake Graetz, President of Precision AQ. "Mike brings a strong combination of financial and operational expertise, along with a deep understanding of our culture, systems, and global teams. His established relationships and knowledge of the business will allow him to make an immediate impact, helping us advance our strategic priorities and strengthen our foundation for continued growth."

As CFO, Mike will partner across the organization to align financial strategy with business priorities, strengthen financial and operational discipline, and help direct investment toward opportunities that support client innovation and growth.

“I’m excited to join Precision AQ at such an important point in its evolution and to build on the momentum across the business,” said Mike. “I look forward to partnering with Jake and the broader leadership team to advance our strategic priorities, invest behind our growth, and help our teams deliver even greater value to our clients. Ultimately, our growth enables us to expand our impact and help more patients access the therapies they need.”

Prior to joining Precision, Mike held senior finance leadership roles at ScienceLogic and GTT Communications, supporting significant growth, acquisitions, and operational transformation. Earlier in his career, he gained extensive M&A and transaction experience at AOL, Constellation Energy, and EY.

Mike holds an MBA from the University of Virginia’s Darden School of Business, as well as a B.S. in Finance and Accounting and a B.A. in Economics from the University of Maryland. He is also a Certified Public Accountant.

About Precision AQ

Precision AQ is the commercialization partner of choice for biopharma innovators, market access leaders, and brand strategists. Trusted by all 30 of the world’s top pharmaceutical companies and leading biotechs, we specialize in transforming complex data into clear, actionable strategies that accelerate access to innovation, including launching 450+ drugs across all therapeutic areas. At Precision AQ, we believe access is enabled by evidence, empathy, and precision. For more information, visit www.precisionaq.com.

Contact:

Hannah Deresiewicz

Precision AQ

hannah.deresiewicz@precisionaq.com